A citation-based method for searching scientific literature

Kai-Keen Shiu, Rachael Natrajan, Felipe C Geyer, Alan Ashworth, Jorge S Reis-Filho. Future Oncol 2010
Times Cited: 17







List of co-cited articles
137 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms.
Rebeqa Gunnarsson, Johan Staaf, Mattias Jansson, Anne Marie Ottesen, Hanna Göransson, Ulrika Liljedahl, Ulrik Ralfkiaer, Mahmoud Mansouri, Anne Mette Buhl, Karin Ekström Smedby,[...]. Genes Chromosomes Cancer 2008
102
29

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Johan Staaf, Göran Jönsson, Markus Ringnér, Johan Vallon-Christersson, Dorthe Grabau, Adalgeir Arason, Haukur Gunnarsson, Bjarni A Agnarsson, Per-Olof Malmström, Oskar Th Johannsson,[...]. Breast Cancer Res 2010
101
29

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
Koei Chin, Sandy DeVries, Jane Fridlyand, Paul T Spellman, Ritu Roydasgupta, Wen-Lin Kuo, Anna Lapuk, Richard M Neve, Zuwei Qian, Tom Ryder,[...]. Cancer Cell 2006
914
29

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.
N Turner, M B Lambros, H M Horlings, A Pearson, R Sharpe, R Natrajan, F C Geyer, M van Kouwenhove, B Kreike, A Mackay,[...]. Oncogene 2010
289
29

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
23

An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
Rachael Natrajan, Britta Weigelt, Alan Mackay, Felipe C Geyer, Anita Grigoriadis, David S P Tan, Chris Jones, Christopher J Lord, Radost Vatcheva, Socorro M Rodriguez-Pinilla,[...]. Breast Cancer Res Treat 2010
125
23

Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
Rachael Natrajan, Maryou B Lambros, Socorro María Rodríguez-Pinilla, Gema Moreno-Bueno, David S P Tan, Caterina Marchió, Radost Vatcheva, Sydonia Rayter, Betania Mahler-Araujo, Laura G Fulford,[...]. Clin Cancer Res 2009
129
23

Resolving the resolution of array CGH.
Bradley P Coe, Bauke Ylstra, Beatriz Carvalho, Gerrit A Meijer, Calum Macaulay, Wan L Lam. Genomics 2007
132
23

Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research.
David S P Tan, Maryou B K Lambros, Rachael Natrajan, Jorge S Reis-Filho. Lab Invest 2007
53
23

Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas.
Felipe C Geyer, Britta Weigelt, Rachael Natrajan, Maryou B K Lambros, Dario de Biase, Radost Vatcheva, Kay Savage, Alan Mackay, Alan Ashworth, Jorge S Reis-Filho. J Pathol 2010
141
23

The genomic profile of HER2-amplified breast cancers: the influence of ER status.
C Marchiò, R Natrajan, K K Shiu, M B K Lambros, S M Rodriguez-Pinilla, D S P Tan, C J Lord, D Hungermann, K Fenwick, N Tamber,[...]. J Pathol 2008
65
23

Breast cancer molecular profiling with single sample predictors: a retrospective analysis.
Britta Weigelt, Alan Mackay, Roger A'hern, Rachael Natrajan, David S P Tan, Mitch Dowsett, Alan Ashworth, Jorge S Reis-Filho. Lancet Oncol 2010
246
23


A census of amplified and overexpressed human cancer genes.
Thomas Santarius, Janet Shipley, Daniel Brewer, Michael R Stratton, Colin S Cooper. Nat Rev Cancer 2010
380
23

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, Suet-Feung Chin, Gulisa Turashvili, Oscar M Rueda, Mark J Dunning, Doug Speed, Andy G Lynch, Shamith Samarajiwa, Yinyin Yuan,[...]. Nature 2012
23


Advances in understanding cancer genomes through second-generation sequencing.
Matthew Meyerson, Stacey Gabriel, Gad Getz. Nat Rev Genet 2010
754
17

A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines.
Alan Mackay, Narinder Tamber, Kerry Fenwick, Marjan Iravani, Anita Grigoriadis, Tim Dexter, Christopher J Lord, Jorge S Reis-Filho, Alan Ashworth. Breast Cancer Res Treat 2009
51
17

Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization.
Maryou B K Lambros, Pete T Simpson, Chris Jones, Rachael Natrajan, Charlotte Westbury, Dawn Steele, Kay Savage, Alan Mackay, Fernando C Schmitt, Alan Ashworth,[...]. Lab Invest 2006
69
17

Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.
Magali Lacroix-Triki, Paula H Suarez, Alan MacKay, Maryou B Lambros, Rachael Natrajan, Kay Savage, Felipe C Geyer, Britta Weigelt, Alan Ashworth, Jorge S Reis-Filho. J Pathol 2010
101
17

Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer.
Isabelle Bernard-Pierrot, Nadège Gruel, Nicolas Stransky, Anne Vincent-Salomon, Fabien Reyal, Virginie Raynal, Céline Vallot, Gaëlle Pierron, François Radvanyi, Olivier Delattre. Cancer Res 2008
70
17

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
17

Hallmarks of 'BRCAness' in sporadic cancers.
Nicholas Turner, Andrew Tutt, Alan Ashworth. Nat Rev Cancer 2004
17

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
Edurne Arriola, Caterina Marchio, David S P Tan, Suzanne C Drury, Maryou B Lambros, Rachael Natrajan, Socorro Maria Rodriguez-Pinilla, Alan Mackay, Narinder Tamber, Kerry Fenwick,[...]. Lab Invest 2008
111
17


Integrated profiling of basal and luminal breast cancers.
José Adélaïde, Pascal Finetti, Ismahane Bekhouche, Laetitia Repellini, Jeannine Geneix, Fabrice Sircoulomb, Emmanuelle Charafe-Jauffret, Nathalie Cervera, Jérôme Desplans, Daniel Parzy,[...]. Cancer Res 2007
226
17

Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?
Rachael Natrajan, Maryou B K Lambros, Felipe C Geyer, Caterina Marchio, David S P Tan, Radost Vatcheva, Kai-Keen Shiu, Daniela Hungermann, Socorro Maria Rodriguez-Pinilla, Jose Palacios,[...]. Genes Chromosomes Cancer 2009
60
17

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,[...]. J Clin Oncol 2010
17

Breast cancer precursors revisited: molecular features and progression pathways.
Maria A Lopez-Garcia, Felipe C Geyer, Magali Lacroix-Triki, Caterina Marchió, Jorge S Reis-Filho. Histopathology 2010
191
17

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
17

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
17

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
17

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. J Clin Oncol 2013
17

The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
Sohrab P Shah, Andrew Roth, Rodrigo Goya, Arusha Oloumi, Gavin Ha, Yongjun Zhao, Gulisa Turashvili, Jiarui Ding, Kane Tse, Gholamreza Haffari,[...]. Nature 2012
17

Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.
Ilan Weinreb, Salvatore Piscuoglio, Luciano G Martelotto, Daryl Waggott, Charlotte K Y Ng, Bayardo Perez-Ordonez, Nicholas J Harding, Javier Alfaro, Kenneth C Chu, Agnes Viale,[...]. Nat Genet 2014
135
17

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, Gong Tang, Chungyeul Kim, Joffre Baker, Maureen Cronin, Frederick L Baehner, Michael G Walker, Drew Watson, Taesung Park,[...]. N Engl J Med 2004
11

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
11



Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.
Soonmyung Paik, John Bryant, Elizabeth Tan-Chiu, Edward Romond, William Hiller, Kyeongmee Park, Ann Brown, Greg Yothers, Steve Anderson, Roy Smith,[...]. J Natl Cancer Inst 2002
372
11

Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Frederick L Baehner, Ninah Achacoso, Tara Maddala, Steve Shak, Charles P Quesenberry, Lynn C Goldstein, Allen M Gown, Laurel A Habel. J Clin Oncol 2010
87
11

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.
Nicholas C Turner, Christopher J Lord, Elizabeth Iorns, Rachel Brough, Sally Swift, Richard Elliott, Sydonia Rayter, Andrew N Tutt, Alan Ashworth. EMBO J 2008
244
11

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Richard M Neve, Koei Chin, Jane Fridlyand, Jennifer Yeh, Frederick L Baehner, Tea Fevr, Laura Clark, Nora Bayani, Jean-Philippe Coppe, Frances Tong,[...]. Cancer Cell 2006
11

Triple negative tumours: a critical review.
J S Reis-Filho, A N J Tutt. Histopathology 2008
649
11

Focal amplification and oncogene dependency of GAB2 in breast cancer.
M Bocanegra, A Bergamaschi, Y H Kim, M A Miller, A B Rajput, J Kao, A Langerød, W Han, D-Y Noh, S S Jeffrey,[...]. Oncogene 2010
54
11

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
11

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
Caterina Marchiò, Maryou B Lambros, Patrizia Gugliotta, Ludovica Verdun Di Cantogno, Cristina Botta, Barbara Pasini, David S P Tan, Alan Mackay, Kerry Fenwick, Narinder Tamber,[...]. J Pathol 2009
164
11

ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.
Daniel G Holland, Angela Burleigh, Anna Git, Mae A Goldgraben, Pedro A Perez-Mancera, Suet-Feung Chin, Antonio Hurtado, Alejandra Bruna, H Raza Ali, Wendy Greenwood,[...]. EMBO Mol Med 2011
100
11




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.